Key result
Diabetes mellitus significantly increased the risk of in-stent restenosis (OR 1.70) and major adverse cardiac events (OR 1.54) after coronary stenting compared to non-diabetic controls.
Why the study?
Does diabetes mellitus increase the risk of adverse clinical outcomes in patients after coronary stenting?
Meta-Analysis (n=128,084)
Does diabetes mellitus increase the risk of adverse clinical outcomes in patients after coronary stenting?
Effect estimate: OR 1.70 (95% CI 1.53-1.89)
Diabetes mellitus is a vital risk factor for adverse clinical outcomes, including in-stent restenosis, stent thrombosis, and MACE, after coronary stenting.
Diabetes heightens post-stent complication risk; confirms DM as an independent predictor and supports intensified secondary prevention.
BACKGROUND: Previous studies have shown inconsistent results on the association between diabetes mellitus (DM) and some clinical outcomes. We conducted a meta-analysis of observational studies to assess effect of DM on clinical outcomes after coronary stenting. METHODS: We searched for studies without language restriction in PubMed, Embase and Cochrane library prior to 2012. The clinical outcomes including in-stent restenosis (ISR), major adverse cardiac events (MACE), stent thrombosis (ST), target lesion revascularization (TLR) and target vessel revascularization (TVR). Adjusted odds ratio (OR), and the corresponding 95% confidence interval (95% CI) was summarized. RESULTS: 55 studies involving 128,084 total patients (38,416 DM patients and 89,668 controls) were eligible for our analysis. Overall, there were significant associations between DM and ISR (OR = 1.70, 95% CI: 1.53-1.89, I(2) = 0.0%), MACE (OR = 1.54, 95% CI: 1.36-1.73, I(2) = 29.0%), ST (OR = 2.01, 95% CI: 1.36-2.97, I(2) = 47.7%), TLR (OR = 1.46, 95% CI: 1.26-1.68, I(2) = 43.3%) as well as TVR (OR = 1.33, 95% CI: 1.17-1.51, I(2) = 48.3). Subgroup analysis showed that the associations were similar between BMS and DES implantation. Moreover, there was no significant association in the ST subgroup after 1-3 years follow-up. CONCLUSIONS: Our meta-analysis suggests that after coronary stent implantation, DM is associated with ISR, MACE, ST, TLR and TVR. DM appears to be a vital risk factor of these clinical outcomes.
No takes yet. Share an insight, caveat, or question.
Qin et al. (2013) conducted a meta-analysis in Coronary artery disease requiring stenting (n=128,084). Diabetes Mellitus vs. Non-diabetic controls was evaluated on In-stent restenosis (ISR) (OR 1.70, 95% CI 1.53-1.89). Diabetes mellitus significantly increased the risk of in-stent restenosis (OR 1.70) and major adverse cardiac events (OR 1.54) after coronary stenting compared to non-diabetic controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: